Should Renal Inflammation Be Targeted While Treating Hypertension?

Effects of Sjogren's Syndrome on essential hypertension: a two-sample mendelian randomization study

BACKGROUND

Sjogren's Syndrome (SS) plays important roles in the development of essential hypertension. Nevertheless, with the limitation of reverse causality and confounder in observational studies, such a relationship remains unclear. We aimed to assess the causal relationship of SS and hypertension by the Mendelian randomization (MR) approach.

METHODS

We used MR to investigate a causal association between SS and essential hypertension. Inverse variance weighted (IVW), MR Egger regression, Maximum likelihood, Weighted median, and MR pleiotropy residual sum and outlier test (MR-PRESSO) were used in this MR analysis.

RESULTS

In this study, we found that the ratio of IVW is 1.00024 (95% CI: 1.00013- 1.00036, P=0.0387), This result was also confirmed by sensitivity analysis methods such as Maximum likelihood is 1.00025 (95% CI: 1.00013-1.00037, P=0.036), MR Egger is 1.00071 (95% CI: 1.00047-1.00095, P=0.0045), and Weighted median is 1.00040 (95% CI: 1.00021- 1.00059, P=0.0322). And MR-Egger intercept method revealed the absence of horizontal pleiotropy in this investigation (P>0.05). The Cochran's Q Test indicated an absence of heterogeneity among them (P>0.05). Heterogeneity and horizontal pleiotropy tests further demonstrate that the results of MR are relatively stable. The above results all suggest that pSS may promote the risk of hypertension.

CONCLUSIONS

Our study provides evidence of a causal relationship of SS and hypertension. It is suggested to pay attention to early screening for hypertension, reduce disability and mortality rates, and improve patient prognosis in patients with SS.

How PPAR-alpha mediated inflammation may affect the pathophysiology of chronic kidney disease

Chronic kidney disease (CKD) is a major risk factor for death in adults. Inflammation plays a role in the pathogenesis of CKD, but the mechanisms are poorly understood. Peroxisome proliferator-activated receptor alpha (PPAR-α) is a nuclear receptor and one of the three members (PPARα, PPARβ/δ, and PPARγ) of the PPARs that plays an important role in ameliorating pathological processes that accelerate acute and chronic kidney disease. Although other PPARs members are well studied, the role of PPAR-α is not well described and its role in inflammation-mediated chronic disease is not clear. Herein, we review the role of PPAR-α in chronic kidney disease with implications for the immune system.

Metabolic Modulators in Cardiovascular Complications of Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a multifactorial disorder with contributions from hormones, genetics, and the environment, predominantly affecting young women. Cardiovascular disease is the primary cause of mortality in SLE, and hypertension is more prevalent among SLE patients. The dysregulation of both innate and adaptive immune cells in SLE, along with their infiltration into kidney and vascular tissues, is a pivotal factor contributing to the cardiovascular complications associated with SLE. The activation, proliferation, and differentiation of CD4+ T cells are intricately governed by cellular metabolism. Numerous metabolic inhibitors have been identified to target critical nodes in T cell metabolism. This review explores the existing evidence and knowledge gaps concerning whether the beneficial effects of metabolic modulators on autoimmunity, hypertension, endothelial dysfunction, and renal injury in lupus result from the restoration of a balanced immune system. The inhibition of glycolysis, mitochondrial metabolism, or mTORC1 has been found to improve endothelial dysfunction and prevent the development of hypertension in mouse models of SLE. Nevertheless, limited information is available regarding the potential vasculo-protective effects of drugs that act on immunometabolism in SLE patients.